- Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease will be highlighted in an oral presentation
- Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term
Lyon, France, March 11, 2021 – MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March 14 – March 17, 2021. The data was previously presented at the American Society of Hematology in December 2020. MaaT013 is an enema formulation of a full ecosystem microbiota biotherapeutic characterized by a consistent high diversity and richness of microbial species derived from pooled healthy donors The results include data from 29 patients with gastrointestinal, acute Graft-versus-Host-Disease (aGvHD) who were resistant to up to 5 lines of treatments and were then treated with MaaT013 as part of an early access program in France. Positive GI aGvHD response at Day 28 was achieved in 59% (17/29) of patients.
As the conference is held virtually this year, the oral presentation by Dr. Florent Malard, Associate Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University who participated in the treatment program, will be recorded and available throughout the duration of the conference in the On-Demand Library section.
Oral presentation details:
Title: Successful And Safe Treatment Of Intestinal GvHD with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program
Session Name: OS8-6
Location: On-Demand Library
Date/Time: March 14 – March 17, 2021 / accessible anytime
In addition to the early access program, MaaT Pharma investigated its lead candidate, MaaT013, in a multi-center, single-arm, open-label, Phase 2 clinical trial, called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refractory, acute GvHD (GI SR-aGvHD) patients (NCT03359980). Topline data from the completed HERACLES clinical trial will be announced shortly.
Full PR available here